May 092012
 
Intermediate magnification micrograph of hepat...

Intermediate magnification micrograph of hepatocellular carcinoma the most common form of primary liver cancer, i.e. the most common form of cancer to arise in the liver. Features on image: End-stage cirrhosis - blue collagen (fibrosis) Mallory bodies. Loss of normal liver architecture. Nuclear atypia. See also Image:Hepatocellular carcinoma low mag.jpg (Photo credit: Wikipedia)

Limits the development of tumours and causes the self-destruction of tumour cells

The combination of two inhibitors of protein mTOR stops the growth of primary liver cancer and destroys tumour cells, according to a study by researchers of the Group of Metabolism and Cancer at Bellvitge Biomedical Research Institute (IDIBELL). The study results are been published on the online edition of the journal Science Translational Medicine.

Primary liver cancer or hepatocellular carcinoma is the fifth most common cancer and, due to its aggressiveness, is the third most deadly. It affects half a million people worldwide. Two of every three cases are related to chronic alcoholism, the exposure of toxic agents or infection with hepatitis B or C. The remaining third is related to non-alcoholic steatohepatitis, a disease related to obesity.

Promising candidates

Currently, the antitumor sorafenib shows the better patient outcomes, but its effectiveness decreases over time. For this reason, it is necessary to find new therapies. Among the most promising candidates are the inhibitors of the mTOR signalling pathway, which is hyperactivated in half of those affected by hepatocellular carcinoma.

The study led by IDIBELL researchers compared the effects in mice of two inhibitors of mTOR. The first was a derivative of rapamycin, called everolimus (RAD001), which is already used as an immunosuppressant and to treat specific cancers. The second is a new generation drug that inhibits mTOR called BEZ235.

During the study, researchers found unexpectedly that the combination of the two drugs had a more potent effect than any of the two drugs separately. Coadministration of BEZ235 and RAD001 limits the development of tumour and causes the self-destruction of tumour cells.

Read more . . .

Bookmark this page for “Liver Tumors” and check back regularly as these articles update on a very frequent basis. The view is set to “news”. Try clicking on “video” and “2” for more articles.

 Leave a Reply

(required)

(required)

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

WordPress Anti-Spam by WP-SpamShield

%d bloggers like this: